The information highlighted (if any) are the most recent updates for this brand.
For long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of non-neuronopathic (type 1) or chronic neuronopathic (type 3) Gaucher disease and who exhibit ≥1 of the following clinically significant non-neurological manifestations of the disease: Anemia, thrombocytopenia, bone disease, hepatomegaly or splenomegaly.